NYSE$BHVN
Biohaven Ltd old · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported third quarter 2022 financial results and recent business developments.
Biohaven Ltd. reported a net loss of $68.9 million, or $1.75 per share, for the three months ended September 30, 2022. The company launched as a new publicly traded company in October and raised gross proceeds of approximately $301.9 million in a public financing.
- Biohaven Ltd. began operating as a separate independent entity in connection with the merger agreement with Pfizer Inc. in May 2022.
- The company closed its underwritten public offering of 28,750,000 common shares at a price of $10.50 per share, raising gross proceeds of approximately $301.9 million.
- Phase 1 studies for BHV-7000, an activator of Kv7.2/Kv7.3, are advancing.
- Enrollment commenced in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in SMA.
Headline financials
Revenue & EPS history
Biohaven · Revenue · Quarterly
$0
Forward guidance
Biohaven expects to reach significant pipeline milestones in the coming periods.
Tailwinds
- Complete Phase 1 studies of BHV-7000 in the first half of 2023 and initiate at least one pivotal trial in patients with epilepsy in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023.
- Provide an update on troriluzole in SCA in the first half of 2023.
- Continue advancing Phase 3 clinical studies of taldefgrobep alfa in SMA.
- Continue advancing early discovery portfolio across multiple neuroscience and immunoscience indications.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q3 2022
-0.5%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+7.7%
Avg return
30 days after
50%
7 / 14 earnings
Positive
+12.6%
Q2 2024
Best reaction
-12.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.7% | -16.0% | -17.0% | |
| Q3 2024 | -6.5% | +0.5% | +28.3% | |
| Q3 2025 | -5.7% | +0.5% | +28.3% | |
| Q2 2025 | -9.0% | +6.6% | -5.0% | |
| Q1 2025 | +0.0% | -3.7% | -5.2% | |
| Q4 2024 | -2.2% | -7.1% | -36.3% | |
| Q2 2024 | +12.6% | +13.7% | +6.7% | |
| Q1 2024 | -12.5% | -8.7% | -17.5% | |
| Q4 2023 | +4.7% | +24.0% | +15.6% | |
| Q3 2023 | +1.0% | +4.6% | +30.9% | |
| Q2 2023 | +3.1% | +3.4% | -3.3% | |
| Q1 2023 | +5.3% | +2.2% | +72.6% | |
| Q4 2022 | +10.4% | +5.4% | +10.8% | |
| Q3 2022 | +1.2% | +2.2% | -0.9% | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro